Table 1.
Clinicodemographic features of patients diagnosed with IDC or ILC, including subgroups of patients diagnosed at or over age 70 years with IDC or ILC
| All included (n = 587,402) | IDC pT1, Age 70 years or older (n = 107,931) | ILC pT1, Age 70 years or older (n = 15,656) | P value | |
|---|---|---|---|---|
| Age | 63 (median) | 75 (median) | 75 (median) | 0.308 |
| 54, 71 (IQR) | 72, 79 (IQR) | 72, 79 (IQR) | 95%CI = − 0.04, 0.13 | |
| Race | White: 502,112 (85.5%) | White: 96,644 (89.5%) | White: 14,086 (90.0%) | < 0.001 |
| Black: 53,094 (9.0%) | Black: 7,305 (6.8%) | Black: 1,193 (7.6%)* | ||
| Non-black/Non-white: 32,196 (5.5%) | Non-black/Non-white: 3,982 (3.7%) | Non-black/Non-white: 377 (2.4%)* | ||
| Insurance | Medicare: 250,530 (42.7%) | Medicare: 95,249 (88.2%) | Medicare: 13,922 (88.9%)* | 0.053 |
| Private: 290,371 (49.4%) | Private: 10,582 (9.8%) | Private: 1,474 (9.4%) | ||
| Medicaid: 32,482 (5.5%) | Medicaid: 1,290 (1.2%) | Medicaid: 160 (1.0%) | ||
| Other government insurance: 6,304 (1.1%) | Other government insurance: 498 ( < 1%) | Other government insurance: 57 ( < 1%) | ||
| Not insured: 7,715 (1.3%) | Not insured: 312 ( < 1%) | Not insured: 43 ( < 1%) | ||
| Charlson-Deyo | 0: 483,132 (82.2%) | 0: 82,611 (76.5%) | 0: 12,303 (78.6%)* | < 0.001 |
| 1: 76,661 (13.1%) | 1: 17,443 (16.2%%) | 1: 2,312 (14.8%)* | ||
| 2: 18,090 (3.1%) | 2: 4,928 (4.6%) | 2: 675 (4.3%) | ||
| 3: 9,519 (1.6%) | 3: 2,949 (2.7%) | 3: 366 (2.3%)* | ||
| Facility type | Comprehensive community: 245,337 (41.8%) | Comprehensive community: 48,278 (44.7%) | Comprehensive community: 6,843 (43.7%)* | < 0.001 |
| Academic program: 171,126 (29.1%) | Academic program: 26,840 (24.9%) | Academic program: 4,208 (26.9%)* | ||
| Integrated network: 127,621 (21.7%) | Integrated network: 23,848 (22.1%) | Integrated network: 3,522 (22.5%) | ||
| Community: 43,318 (7.4%) | Community: 8,965 (8.3%) | Community: 1,083 (6.9%)* | ||
| Facility location | East Central: 133,915 (22.8%) | East Central: 25,300 (23.4%) | East Central: 3,550 (22.7%)* | < 0.001 |
| South Atlantic: 129,455 (22.0%) | South Atlantic: 24,604 (22.8%) | South Atlantic: 3,543 (22.6%) | ||
| West Central: 91,585 (15.6%) | West Central: 16,576 (15.4%) | West Central: 2,256 (14.4%)* | ||
| Middle Atlantic: 87,132 (14.8%) | Middle Atlantic: 15,865 (14.7%) | Middle Atlantic: 2,567 (16.4%)* | ||
| Pacific: 80,914 (13.8%) | Pacific: 14,024 (13.0%) | Pacific: 1,934 (12.4%)* | ||
| New England: 35,118 (6.0%) | New England: 6,481 (6.0%) | New England: 1,066 (6.8%)* | ||
| Mountain: 29,283 (5.0%) | Mountain: 5,081 (4.7%) | Mountain: 740 (4.7%) | ||
| Hormonal status | ER+PR+HER2-: 521,304 (88.7%) | ER+PR+HER2-: 96,889 (89.8%) | ER+PR+HER2-: 13,158 (84.0%)* | < 0.001 |
| ER+PR-HER2-: 61,265 (10.4%) | ER+PR-HER2-: 10,388 (9.6%) | ER+PR-HER2-: 2,480 (15.8%)* | ||
| ER-PR+HER2-: 4,833 ( < 1.0%) | ER-PR+HER2-: 654 ( < 1.0%) | ER-PR+HER2-: 18 ( < 1.0%)* | ||
| Clinical T-stage | cT1a: 41,384 (7.0%) | cT1a: 11,376 (10.5%) | cT1a: 1,199 (7.7%)* | < 0.001 |
| cT1b: 134,386 (22.9%) | cT1b: 36,104 (33.5%) | cT1b: 4,877 (31.2%)* | ||
| cT1c: 176,361 (30.0%) | cT1c: 34,722 (32.2%) | cT1c: 5,715 (36.5%)* | ||
| cTo: 235,271 (40.1%) | cTo: 25,729 (13.8%) | cTo: 3,865 (24.7%)* | ||
| Pathologic T-stage | pT1a: 54,058 (9.2%) | pT1a: 14,445 (13.4%) | pT1a: 1,192 (7.6%)* | < 0.001 |
| pT1b: 135,792 (23.1%) | pT1b: 38,093 (35.3%) | pT1b: 4,331 (27.7%)* | ||
| pT1c: 220,975 (37.6%) | pT1c: 53,833 (49.9%) | pT1c: 9,944 (63.5%)* | ||
| pTo: 176,577 (30.1%) | pTo: 1,560 (1.4%) | pTo: 189 (1.2%)* | ||
| Axillary staging | Sentinel Lymph Node Biopsy: 479,825 (81.6%) | Sentinel Lymph Node Biopsy: 85,949 (79.6%) | Sentinel Lymph Node Biopsy: 12,761 (81.5%)* | < 0.001 |
| None: 47,667 (8.1%) | None: 17,150 (15.9%) | None: 2,216 (14.2%)* | ||
| Axillary dissection: 59 ,910 (10.2%) | Axillary dissection: 4 ,832 (4.5%) | Axillary dissection: 679 (4.3%) |
* Indicates statistical significance between headings within categorical variables using differences in proportions. IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, IQR Interquartile range, CI Confidence interval, ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2, T Tumor, c Clinical, p Pathologic, a/b/c Tumor substage, o Other (not T1a/T1b/T1c), + indicates positive expression, − indicates negative expression